{"id":"W4417008388","doi":"10.1182/blood-2025-884","title":"Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"Chemoimmunotherapy; Mantle cell lymphoma; Rituximab; Phases of clinical research; Progressive disease; Clinical endpoint; Minimal residual disease; Lymphoma; Ibrutinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001495712,0.0006315317,0.00116672,0.0002446122,0.0002121678,0.000927898,0.0005235129,0.0005862323,0.001910746],"category_scores_gemma":[0.001115764,0.0003181102,0.001206776,0.0003732914,0.0003220304,0.0006511165,0.0002978287,0.001383614,0.0004346199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009894808,"about_ca_system_score_gemma":0.0009405625,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001481523,"about_ca_topic_score_gemma":0.003889478,"domain_scores_codex":[0.999429,0.0003209364,0.00003586847,0.00008209505,0.00006380394,0.00006811821],"domain_scores_gemma":[0.9994155,0.0001065181,0.0001449234,0.00005021404,0.00004444057,0.0002384971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7256936,0.04057748,0.04963943,0.0009050693,0.004402402,0.0003292004,0.0004795,0.001525052,0.02359637,0.0002577328,0.005819351,0.1467747],"study_design_scores_gemma":[0.4452919,0.4400952,0.09952027,0.00009596963,0.002815115,0.0006694539,0.0001833138,0.001494792,0.001642354,0.0002388929,0.007897297,0.00005546388],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938411,0.003127623,0.0001805358,0.0002231174,0.00004679017,0.0005076786,0.0007663791,0.0000397441,0.001266946],"genre_scores_gemma":[0.9936559,0.001440597,0.0005560811,0.0005822094,0.000140157,0.0005577403,0.002133927,0.00001437996,0.0009190725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001910746,"threshold_uncertainty_score":0.007910132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009038424887865857,"score_gpt":0.2500816424486637,"score_spread":0.2410432175607979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}